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Abstract
Human tissue kallikreins (KLKs) are members of a multigene family of serine proteases aberrantly expressed in many cancer
types. In ovarian cancer, 12 KLKs are upregulated, and of those KLK5, 6 and 10 have been the focus of investigations into
new diagnostic and prognostic biomarkers. However, little is known about the contributions of KLK5, 6 and 10 to ovarian
cancer pathophysiology. In this study, a panel of 13 human ovarian cancer cell lines was screened by ELISA for secretion of
KLK5, 6, 8, 10, 13, and 14. The ES-2 cell line, devoid of these kallikreins, was transfected with expression vectors of KLK5, 6
and 10 individually or in pairs. Co-expression of KLK5, 6 and 10 was correlated with lessened aggressivity of ovarian cancer
cell lines as defined by reduced colony formation in soft agar and tumorigenicity in nude mice. ES-2 clones overexpressing
KLK5, 10/5, 10/6, 5/6 made significantly fewer colonies in soft agar. When compared to control mice, survival of mice
injected with ES-2 clones overexpressing KLK10, 10/5, 10/6, 5/6 was significantly longer, while KLK6 was shorter. All groups
displaying a survival advantage also differed quantitatively and qualitatively in their presentation of ascites, with both a
reduced incidence of ascites and an absence of cellular aggregates within those ascites. The survival advantage conferred
by KLK10 overexpression could be recapitulated with the exogenous administration of a recombinant KLK10. In conclusion,
these findings indicate that KLK5, 6 and 10 may modulate the progression of ovarian cancer, and interact together to alter
tumour pathophysiology. Furthermore, results support the putative role of KLK10 as a tumour suppressor and suggest it
may hold therapeutic potential in ovarian cancer.
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Introduction
The recently discovered tissue kallikreins are a family of secreted
serine proteases encompassing 15 members (KLK1-15) whose
genes (KLK1-15) are clustered in tandem on a 300 kb region on
chromosome 19q13.4 [1]. KLK proteins are detected in many
biological fluids including blood, seminal plasma, sweat, saliva,
cerebrospinal fluid, milk, and interstitial spaces where they can be
activated and/or inactivated by enzymatic cleavage [2]. KLKs
cleave a broad range of substrates including extracellular matrix
(ECM) proteins, insulin-like growth factor binding proteins,
protease-activated receptors (PAR), other kallikreins and even
themselves [2]. Moreover, KLKs are often expressed in groups,
such as KLK3, 4, 5, 6, 8, 10, 13 and 14 in the breast or KLK2, 3,
4, 5, 11, and 15 in the prostate [2]. These observations have led to
the hypothesis that kallikreins can act in a cascade to mediate their
biological effects, also known as the KLK activome [3]. For
example, preliminary evidence suggests that KLK5 may be an
initiator of KLK cascades, capable of activating pro-KLK2, 3, 6,
7, 11, 12, 14, resulting in the degradation of ECM components of
semen, and liquefaction [4].
Kallikreins have been implicated in a number of diseases such as
Alzheimer’s and multiple sclerosis [5,6], inflammatory bowel
disease [7], arthritis [8], sepsis [9], diabetes [10], skin diseases [11]
and cancer [12]. Because KLKs are secreted and readily
detectable in biological fluids, they have emerged as potentially
valuable biomarkers, particularly in cancer, where KLK3 (also
known as prostate specific antigen) has proven to be useful for
prostate cancer monitoring. Most KLK expression is under
hormonal control, and the responsiveness of KLK2 and 3 to
androgens in prostate cancer cell lines [13], and KLK6 and 10 to
estrogens in breast cancer cell lines is well documented [14,15].
The pattern of expression of KLKs, as well as their hormonal
regulation, suggests they may be involved in endocrine-related
adenocarcinomas of the reproductive tract such as prostate, testis,
breast, cervical, and ovarian cancers.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26075Accumulating evidence suggests that at least 12 of the 15
kallikreins are upregulated in ovarian cancer. Of those, KLK4, 5,
6, 7, 10, and 15 are associated with unfavorable prognosis while
the expression of KLK8, 9, 11, 13, and 14 is associated with a
favorable prognosis [12]. This study focuses on KLK5, 6 and 10
which are frequently overexpressed in ovarian cancer and found in
elevated levels in the ascites and serum of patients [16–18].
Notably, serum KLK6 and KLK10 are indicators of poor
prognosis [19,20], and high KLK6 is associated with shorter
recurrence-free survival and lower overall survival [21]. High
levels of KLK10 in the serum are associated with advanced stage
serous tumours with large residual disease and poor response to
chemotherapy [22], while low levels of KLK10 in the tumour
predict poor overall survival [23]. The histological subtypes of
epithelial ovarian cancers, such as serous, mucinous, endometroid,
clear cell and undifferentiated tumours may reflect distinct
ontogenies and are becoming increasingly important in tailoring
treatment [24]. The expression of KLKs is remarkably similar
across histological subtypes. For example, all subtypes express
KLK6, with perhaps a slightly higher proportion of clear cell
tumours that display strong immunostaining for KLK6 [21,25].
Similarly, patients with tumours of each subtype have detectable
levels of KLK10 in their cytosols, with a slight but significantly
higher proportion of KLK10 high patients being of the serous
subtype [26]. Finally, KLK5 expression appears to be more
prevalent in serous and undifferentiated tumours [27,28].
While little is known about the biological basis for the
contribution of KLK5, 6 and 10 to ovarian cancer, the ability of
KLK5 and 6 to cleave ECM proteins [4,29], and activate PAR
signaling [30], suggest that they are directly implicated in various
aspects of carcinogenesis. Degradation of ECM components may
facilitate the detachment of malignant cells from the tumour and
the invasion of normal tissues, while some of the released ECM
peptides may have both pro and anti-angiogenic qualities [29,31].
Moreover, PAR signaling has important roles in vasoregulation,
cell growth and inflammation [32,32,33]. KLK10 was identified as
a putative tumour suppressor in breast [34] and gastric cancers
[35], and is often silenced in ovarian cancer cell lines and tumours
[36], despite its expression in the serum being an unfavorable
prognostic marker. This apparent paradox exemplifies the
dichotomy of kallikreins as both positive and negative regulators
of processes involved in carcinogenesis such as angiogenesis,
growth, invasion, and metastasis [37].
While evidence of aberrant expression of multiple kallikreins in
ovarian cancer is mounting, little is known about their contribu-
tion to the pathophysiology of the disease. Herein we report the
first attempt to unravel the contributions of KLK5, 6 and 10 in a
xenograft model of ovarian cancer, and the first therapeutic use of
a recombinant KLK10 protein in vivo.
Materials and Methods
Cell culture
The origin [38], and the type of tumours formed in xenografts
[39] for the ovarian cancer cell lines Caov-3 (adenocacinoma
[40]), OVCAR-3 (mildly differentiated serous adenocarcinoma
[41]), OVCAR-4 (adenocarcinoma [42]), OV2008 (endometreoid
adenocarcinoma with squamous differentation [39]), C13 (en-
dometreoid adenocarcinoma with squamous differentation [39]),
OVCA433 (adenocarcinoma [43]), SKOV-3 (clear cell adenocar-
cinoma [39]), OVCA429 (clear cell adenocarcinoma [39]), Hey
(undifferentiated [39]), ES-2 (undifferentiated [39]), OCC-1
(undifferentiated [39]), A2780cp (undifferentiated [39]), and
A2780s (undifferentiated [39]) used in this study as well as their
culture conditions were described in a previous publication [39].
The cell lines HT1080 and NIH3T3, used as controls, were
procured from ATCC (Manassas, VA, USA) and cultured
according to their recommendations.
Construction of stably transfected ES-2 cell lines over-
expressing kallikreins
The plasmids pcDNA3.1D/V5-His/lacZ (Invitrogen, Missis-
sauga, ON, Canada) with geneticin resistance, and pIRESpuro-2
(Clonetech, VWR, Mississauga, ON, Canada) with puromycin
resistance were used as backbones and stably transfected into the
ES-2 cell line to provide vector controls. In short, multiple clones
stably transfected with pIRESpuro-2 were used as single vector
controls, and multiple clones successively transfected by
pcDNA3.1.1D/V5-His/lacZ and pIRESpuro-2 were used as
double vector control. The cDNAs for KLK5, KLK6 and
KLK10, as well as the pcDNA-KLK5 expression construct on a
pcDNA3.1D/V5-His-TOPO backbone, were kindly provided by
Dr. E.P. Diamandis (Toronto, ON, Canada). The KLK10
expression vector in pCMV-neo was provided by Goyal et al. and
has been previously described [44]. Briefly, PCR amplification,
restrictiondigestionand ligation ofDNAfragments representingthe
cDNAs of KLK5, 6, and 10 into the expression vectors pIRESpuro-
2 were performed, and the resulting constructs were stably
transfected into ES-2 cells. A minimum of 3 clones of each were
picked and one was randomly chosen to derive the respective cell
lines ES-2-KLK5, ES-2-KLK6, and ES-2-KLK10 for in vivo
experiments.For doubletransfectants,a minimum of3 independent
clones of pCMV-neo expressing KLK10 were further transfected
withthe pIRES-puro-2 expressing KLK5 or KLK6 and one of each
was randomly chosen to generate respectively the ES-2-KLK5/10
and ES-2-KLK6/10 cell lines. The cell line ES-2-KLK5/6 was
generated from one of the 3 clones by stably transfecting the ES-2-
KLK6 cell line with the pcDNA-KLK5 construct. Transfection of
ES-2 cells was carried out using Lipofectomine
TM 2000 (Invitrogen,
Mississauga, ON, Canada) according to the protocol provided by
the manufacturer. The clones described above were selected and
maintained in DMEM media (Thermo Scientific, Waltham MA,
USA) containing geneticin (400 mg/ml) and/or puromycin (10 mg/
ml) (Gibco BRL, Carlsbad, CA, USA).
Cell Proliferation Assay
To evaluate proliferation, cell growth was analyzed in the
parental ES-2 cells lines and 3 or more clones stably transfected
with constructs for KLK5, KLK6, KLK10, KLK5/6, KLK5/10,
KLK6/10 or Vector control using 12-well plates with initial
plating densities of 10,000 cells/well. After 96 hours, cells were
trypsinized and subsequently counted with a Coulter Counter
(Beckman Coulter Inc., Fullerton CA, USA).
Anchorage independent growth
The protocol used was previously described by M. Pace et al
[45]. Briefly, 5610
3 cells were suspended in 3 ml complete media
containing 3.5% low melting-point agarose and poured on top of
the bottom layer of 7% agarose in the same medium in wells of a
6-well plate. Media (0.5 ml) was added to each well and changed
every 2–3 days. A solution of p-iodonitrotetrazolium violet (1 ml)
was added to each well at day 7 and colonies were stained for
24 hours, counted, and photographed.
Invasion assay
For the invasion assay on the kallikrein overexpressing clones,
we used the HTS transwell 96 systemH (Corning, Lowell, MA).
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extracts as instructed by the manufacturer, and 5610
4 cells in
50 ml serum-free media were then added to the top chamber,
while 150 ml of media with 10% serum were added to the
reservoir. The plate was incubated at 37uCi n5 %C O 2
atmosphere for 24 hours. The cells which migrated to the bottom
of the insert were stained with hematoxylin according to the
manufacturer’s protocol, and the membranes were mounted on
slides, scanned using the ScanScope (Aperio, Vista, CA), and the
amount of blue pixels was quantified using the Aperio software
(Aperio, Vista, CA). Data was plotted as % invasion, when
compared to the amount of cells on a control transwell membrane
not coated with basement membrane extracts.
Xenograft
All animal experiments performed in this study were in
compliance with the Guidelines for the Care and Use of Animals
established by the Canadian Council on Animal Care, and were
approved by the Animal Care Committee at the University of
Ottawa (Protocol ME-196). Female CD-1 nu/nu mice (Charles
River Laboratory, Wilmington, MA, USA) aged 5–6 weeks were
housed with food and water ad libitum, on a 12 h daylight cycle.
The tumour cell IP xenograft method was described previously
[39]. Briefly, after one week of acclimatization, the mice were
injected intraperitoneally (IP) with 10
7 ES-2 cells, or one of its
derivative clones chosen at random from the cell lines stably
transfected with KLK5, KLK6, KLK10, KLK5/6, KLK5/10,
KLK6/10, Vector single control, or Vector double control,
resuspended in 0.8 ml of phosphate-buffered saline. Groups were
then blinded to ionvestigators until the end of the experiment at
day 56. Disease progression was monitored daily, based on a set of
general wellness criteria set by the animal care committee, and
body mass was recorded twice a week until a predetermined
endpoint was reached. The time at which symptoms of the disease
first appeared, such as mild abdominal distension, or small
palpable mass was recorded. Endpoints included: dehydration
and/or weight loss of over 15% despite fluid therapy, any evidence
of respiratory distress, body weight increase of over 5 g from the
average body weight of control mice at the same age in the same
population, presence of a palpable abdominal mass that impairs
mobility, feeding or affects wellness and finally presence of
abdominal distension that impairs mobility or affects wellness or
causes significant discoloration evident on the dorsal or ventral
skin.
Upon necropsy, tumour samples were weighed and divided to
be either immediately flash-frozen in liquid nitrogen and stored at
220uC, or fixed in 10% buffered formalin (VWR, Mississauga,
ON, Canada) for 24 hours and stored in 70% ethanol prior to
processing into paraffin-embedded blocks, which were cut into
5 mm sections for hematoxylin and eosin (H&E) staining. Ascites
volume was measured, and the samples were assessed microscop-
ically to determine the presence of cellular aggregates. Samples
were then spun at 25006 g for 10 minutes to collect the
supernatant for storage at 220uC for subsequent measurements
of KLK levels by ELISA.
Blood sampling
For the survival experiment, blood samples were taken one
week prior to injection and weekly until either the animal reached
endpoint or the experimental period ended at day 56. Blood was
also taken before necropsy whenever possible. For the recombi-
nant KLK10 blood clearance and toxicity experiment, each
dosage group (0, 0.2, 1, and 5 mg) had one animal per timepoint
(21 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h). To recover the
plasma, 100–200 ml of blood was acquired by saphenous vein
puncture with a 25G5/8 gauge needle (BD, Franklin Lakes, NJ,
USA) and collected into microvettesH CB300LH (Sarstedt,
Germany) coated with heparin, centrifuged 5 min at 2000 g,
and the plasma layer was separated to be stored at 220uC until
the ELISAs were performed.
ELISA of kallikreins
For the panel of ovarian cancer cell lines, cells were cultured in
24-well plates with 5610
4 cells and 1 ml of media per well. Media
samples were collected after incubation at 37uC for 3 days.
ELISAs for KLK5 [46], KLK6 [47], KLK8 [48], KLK10 [49],
KLK13 [50], and KLK14 [51] were performed according to the
protocols published previously. ELISAs for the KLK5, 6 and 10
were performed on media of ES-2 clones after 24 h of culture on
the day of xenograft implantation. Similarly, ELISA were
performed on both human ascites samples and mouse serum
and ascites samples diluted from 5-fold to 8000-fold, depending on
the KLK concentration, in a dilution buffer (50 mM Tris-Cl
pH7.8, with 60 mg/ml of BSA and 0.5 mg/ml of sodium azide).
Recombinant KLK10 production
KLK10 cDNA was amplified by PCR using oligos KLK10FP
(TATACGTAGCGCTGCTCCCCCAAAACGACAC) and KLK-
10RP (GTCCTAGGATCGATTGGAGCGTATGAC) [44] from a
pCMV-neo vector carrying KLK10 cDNA. After double digestion
with SnaBIa n dAvrII, the amplified DNA fragment was inserted into
pPIC-9, pre-digested with SnaBIa n dAvrII. The resulting plasmid,
pPIC-KLK10, was then transformed into the Pichia pastoris host strain
KM71 by electroporation (Pichia Expression kit, Invitrogen life
technologies).
Fermentation of 15-litres of recombinant KLK10 was conducted
using a BIOSTAT H ED fermenter (B.Braun Biotech International,
Allentown, PA, USA) and a process based on Pichia fermentation
Process Guidelines from Invitrogen. Briefly, fermenter was
inoculated with yeast prepared in a 2800 ml shaker-flask for a
starting OD600 of ,0.3. After a 20-hour glycerol batch phase, a 4-
hour glycerol feed phase was followed. Induction was initiated by
starting glycerol feeding and lasted for about 40 hours. Cells were
removed by centrifugation and supernatant was collected.
Purification of KLK10 from the supernatant was carried out
using a CM-sepharose column (Amersham Biosciences, ON,
Canada) as described previously [49].
Treatment with recombinant KLK10
For the blood clearance experiment, we first tested single bolus
IP doses of recombinant KLK10 (0, 0.2, 1, and 5 mg in 1 ml) with
5 nu/nu mice per dose and sampled the blood at various time
points as described above. The animals were closely monitored for
the first 12 h, and then periodically for 15 days before being
sacrificed.
For the toxicity experiment we tested doses of 0, 50, 200, and
800 mg in 1 ml of KLK10, administered daily IP in 3 animals per
group for 7 days, followed by 7 days of daily monitoring with no
treatment before being sacrificed. At necropsy, the liver, lung,
heart and kidney were removed and divided to be either
immediately flash-frozen and stored at 220uC or fixed in 10%
buffered formalin (VWR, Mississauga, ON, Canada) for 24 hours
and stored in 70% ethanol prior to processing into paraffin-
embedded blocks, which were cut into 5 mm sections for H&E
staining. Sections were analyzed for signs of inflammation and
damage.
For the therapeutic experiment, the nude mice were randomly
divided into one control and 2 treatment groups (8 animals/
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8 weeks post-xenograft. Animals still alive at the end of the study
were sacrificed. On day 1, animals were injected IP with 0.2 ml
of PBS buffer, or 0.2 ml of PBS containing 5 mg of KLK10
followed immediately by an injection of 10
7 ES-2 cells
resuspended in 0.8 mL PBS buffer. From then on, 1 ml of
PBS buffer or 1 ml of PBS containing 5 mg of KLK10 were
injected IP to each animal either daily or twice daily (as
indicated) from day 2 to day 14.
For the in vitro treatment experiment, 10
5 ES-2 cells per well
were seeded in a 12-well plate containing either serum-free
DMEM or DMEM with 10% fetal calf serum, and supplemented
with 4 doses or recombinant KLK10 (0, 300 ng/ml, 3000 ng/ml
and 30000 ng/ml) for 96 h. Cell viability was determined by
trypan blue exclusion and cells were counted using a ViCell
Counter (Beckman Coulter, Fullerton, CA).
Survival curves and statistical analyses
Kaplan-Meier survival curves were plotted using GraphPad
Prism 4.0 software (Graphpad Software, San Diego, CA, USA)
and compared using a logrank test. Pathophysiological param-
eters such as ascites volume and tumour burden (total tumour
mass excised) and results from in vitro experiments were
compared by one-way ANOVA followed by Tukey’s post test.
Proportions such as incidence of aggregates or ascites were
compared by CHI square. Statistical significance was inferred at
p,0.05.
Results
Secretion of kallikreins 5, 6 and 10 correlates with
reduced aggressiveness in a panel of ovarian cancer cell
lines, yet is detectable in the ascites of ovarian cancer
patients
Expression of the kallikrein cluster including KLK4 to KLK14
has previously been reported in ovarian cancer [37]. However it has
also been reported that different kallikreins can have diametrically
opposed effects on patient prognosis in a variety of cancers [37]. To
verify that kallikrein expression is recapitulated in ovarian cancer
cell lines, a panel of thirteen ovarian cancer cell lines (CAOV-3,
OVCAR-3, OVCAR-4, OV2008, C13, OVCA433, SKOV-3,
OVCA429, Hey, ES-2, OCC-1, A2780cp, A2780s) was screened
for secretionof KLK 5,6, 8,10,13 and 14 into the culture media by
ELISA(TableS1).Onthebasisofkallikreinexpression,thecelllines
could be segregated into non-expressors (SKOV-3, OVCA429,
Hey, ES-2, OCC-1, A2780cp, A2780s) and expressors (CAOV-3,
OVCAR-3, OVCAR-4, OV2008, C13, OVCA433). In the latter
group, all shared common expression of KLK5/6, and 5 of 6
expressed KLK10, 4 of 6 KLK8, 3 of 6 KLK13 and none expressed
KLK14. To investigate any link between kallikrein expression and
aggressiveness of the cell lines, these two groups were compared for
their ability to invade into matrigel, form colonies in soft agar and
develop tumours intraperitoneally in nude mice (data not shown). A
loose correlation was observed, albeit with some exceptions, that in
contrast to the non-expressors, the cells expressing kallikreins did
not invade matrigel, did not form colonies in soft agar, and as
previously reported by us [39], were very poor at forming tumours
in nude mice (Table 1).
Stable overexpression of KLK 5, 6 and 10, alone or in
pairs, in clones of the kallikrein-deficient ES-2 cell line,
results in altered anchorage-independent growth but
does not affect cellular proliferation or invasive potential
KLK5, 6 and 10 were the most commonly expressed kallikreins
in the less aggressive ovarian cancer cell lines suggesting a
correlation between the expression of those kallikreins and
tumourigenic potential. To tease apart the roles of each kallikrein
and their interactions on tumourigenicity, ES-2 cells which do not
express any of the tested kallikreins (Table 1) were stably
transfected with expression vectors for KLK5, 6, 10 alone or in
pairs. 3 or more clones of KLK5, 6, 10, 5/6, 5/10, 6/10 along
with empty plasmid control and unmodified ES-2 cells were
compared for anchorage-independent growth, proliferation and
invasion (Fig. 1). Expression of KLK5, 5/6, 5/10, and 6/10 was
sufficient to significantly reduce the ability of ES-2 cells to form
Table 1. Kallikrein expression profile and tumorigenicity in a panel of 13 ovarian cancer cell lines.
Cell lines
KLK secretion
(in media)
Invasion
(matrigel)
Colony formation
(agarose) Xenografts (mice) [39]
Tumour incidence Median Survival (days)
CAOV-3 5,6,8,10 22 Unknown N/A
OVCAR-3 5,6,8,10 22 0/6 N/A
OVCAR-4 5,6,8,10,13 22 Unknown N/A
OV2008 5,6,8,10,13 22 4/5 66
C13 5,6,10,13 22 0/5 N/A
OVCA433 5,6 22 0/3 N/A
SKOV-3 ND +/2 +/2 2/7 105
OVCA429 ND ++ 3/3 62
HEY ND ++ 2/3 24
ES-2 ND ++ 5/5 16
OCC-1 ND 2 + 3/3 15
A2780cp ND 2 + 3/3 24
A2780s ND 2 + 3/3 46
ND=not detectable. N/A=Not applicable.
doi:10.1371/journal.pone.0026075.t001
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e26075Figure 1. Clones overexpressing KLK5, 6 and 10, alone or in pairs, display differential anchorage-independent growth but do not
differ in proliferation or invasive capacity. Three or more clones of the ES-2 cell line overexpressing KLK5, 6 or 10 or pairs of KLK5/6, KLK5/10
and KLK6/10 were compared to parental ES-2 cells or vector-transfected controls in vitro for their tumourigenic potential. A) Clones were grown in
soft agar and the number of colonies was counted and is represented as percentage of the cells which formed colonies. B) Clones were grown for
96 h in serum-containing media and cell numbers were counted. C) Clonal cells resuspended in serum-free media were deposited in an insert coated
with basement membrane extract and allowed to invade the transwell bathing in media with 10% serum for 24 h and migrating cells were
quantified. The results are shown as the mean of 3 or more clones +/2 SEM, and significance is inferred by one-way ANOVA with post test if p,0.05.
Different lower-case letters above each bar indicate statistically significant differences between values (p,0.05). In C, the data are normalized to the
parental control.
doi:10.1371/journal.pone.0026075.g001
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did not alter the rate of proliferation over 96 h or modulate the
ability of the clones to invade in a transwell assay.
Stable overexpression of KLK 5, 6 and 10, alone or in
pairs, in clones of the kallikrein-deficient ES-2 cell line,
results in altered survival of a mouse xenograft model
To investigate whether differential kallikrein expression could
regulate the aggressiveness of ovarian cancer cells in vivo, an intra-
peritoneal (IP) xenograft model was employed. For this purpose
the ES-2 ovarian cancer cell line is ideal, since it does not express
kallikreins 5, 6 and 10 (Table 1) and readily forms rapidly-
progressing tumours IP in nude mice that are accompanied by
ascites, thus mimicking disease progression in humans [39]. Clones
derived from this cell line, stably secreting KLK5, 6, 10, 5/6, 5/10
and 6/10 in the culture media along with the appropriate empty
vector controls (Table 2) were injected IP in immunodeficient nu/
nu mice. The mice were injected with 10
7 cells of each clone per
animal, in groups of 8, which were then blinded, and closely
monitored for endpoints. Median survival times for the parental
line was 16d whereas the single expressor control was 19.5d and
the double expressor control was 15d. Survival of the group
expressing KLK5 (24.5d) did not differ from the control group
(Fig. 2), while survival of the groups expressing KLK10 (32.5d),
KLK5/6 (25.5), KLK5/10 (23.5), and KLK6/10 (23.5) was
significantly longer than their appropriate controls by logrank test
(Fig. 2). Survival of the group overexpressing KLK6 (15d) alone
was significantly shorter than the control cell line but not the
parental line. The groups KLK5, KLK10, KLK5/6 and KLK5/
Table 2. Stable overexpression of KLK5, 6, and 10 alone or in
pairs, in clones of the ES-2 cell line results in secretion of
kallikreins into the culture media.
ES-2 clone Kallikrein concentration in media (ng/ml)
KLK5 KLK6 KLK10
Parental ,0.2 ,0.2 ,0.5
Single vector control ,0.2 ,0.2 ,0.5
Double vector control ,0.2 ,0.2 ,0.5
KLK5 227 ,0.2 ,0.5
KLK6 ,0.2 352 ,0.5
KLK10 ,0.2 ,0.2 316
KLK5/6 58 202 ,0.5
KLK5/10 74 ,0.2 40
KLK6/10 ,0.2 260 1400
doi:10.1371/journal.pone.0026075.t002
Figure 2. Clones overexpressing of KLK5, 6 and 10, alone or in pairs, differentially affect survival times when xenografted into nude
mice. A) Clones of the ES-2 cell line overexpressing KLK5, 6 or 10 or B) pairs of KLK5/6, KLK5/10 and KLK6/10 were injected IP in nude mice and
survival was compared to control mice xenografted with the appropriate vector backbone clones. The results are shown as a Kaplan-Meier plot, and
significance using a logrank test versus appropriate control was inferred at p,0.05. * denotes p,0.05, ** denotes p,0.01, and *** p,0.001.
doi:10.1371/journal.pone.0026075.g002
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KLK6/10 had two, upon study termination at day 56, whereas all
the mice in the control groups developed disease.
Mice xenografted with kallikrein-secreting tumours
display changes in pathophysiology
To clarify the link between KLK secretion and survival, several
disease-related metrics were compared across all groups upon
necropsy (Table 3). The most prevalent endpoint was abdominal
distension (82%) resulting from ascites accumulation, followed by
respiratorydistress(8%)causedbypleuraleffusions,dehydrationand
weight loss (7%), and finally impaired mobility (3%). Some animals
were not measured in the endpoint statistics because of the absence
ofdisease uponstudytermination(N=8),orbecausetheydied ofthe
disease prior to being endpointed (N=6). Tumour histology, spread
and sites of metastases were similar amongst groups, with a
preference for the omentum, peritoneal membrane, diaphragm,
reproductive organs, liver and intestines. Both tumour burden and
ascites volume were recorded in animals who reached endpoint, and
non-zero values were used to calculate the mean (Table 3). Mean
ascites volume did not differ between groups with the notable
exception of control-double which progressed past their distension
endpoint before being sacrificed becauseoftheir rapid rate of disease
progression. A statistically significant lowered incidence of ascites at
necropsywasobserved inanimals ofgroups KLK5/10 (p,0.01) and
KLK6/10 (p,0.01) with only 37.5% occurrence rate when
compared to control groups which all developed ascites. Paradox-
ically, the KLK6/10 group also had on average a higher tumour
burden (p,0.01), likely because of the longer ascites-free survival.
Amongst the animals that did develop ascites within the groups of
KLK5, KLK10, KLK5/6, KLK5/10, KLK6/10, a significantly
lower incidence of multicellular free-floating aggregates in the ascites
was recorded (Table 3). The aggregates present in the ascites were
compact spheres of cells of uniform size (,1m m
3) visible to the
naked eye. The kallikrein concentrations measured by ELISA in the
ascites showed levels of KLK6 (Table 3) to be comparable to levels
seen in patient ascites, while levels of both KLK10 and KLK5 were
elevated in comparison to the patient samples, especially in the
combination groups.
The survival time of each group of mice can be divided into a
period prior to onset of symptoms, followed by a symptomatic
period which culminates at endpoint. Variability between groups
is already present when looking at the onset of symptoms (Table 3),
suggesting kallikreins may affect early disease progression. To
follow the early disease progression, plasma kallikrein levels were
measured by ELISA in each animal weekly and upon necropsy, to
serve as a surrogate marker of tumour burden. Kallikreins were
detectable in the plasma well before the onset of the first symptoms
in all mice, suggesting that asymptomatic trace disease is
detectable by measuring circulating kallikreins. In all groups,
serum concentration quickly rises and culminates with endpoint as
seen in the last three measurements (Fig. 3). Additionally, the
surviving tumour-free animals of groups KLK5/6, KLK5/10, and
KLK6/10 (Fig. 2B) did not display any detectable levels of
kallikreins in the plasma for the duration of the study.
Intraperitoneal administration of recombinant KLK10
recapitulates increased survival in an ES-2 xenograft
model
To further confirm that the observed anti-tumourigenic effects
of kallikreins were specific, a survival experiment using recombi-
nant KLK10 was performed since, as a single agent, it showed the
most promise (Fig. 2A). A pilot study was first conducted to ensure
the recombinant KLK10 had no side effects in healthy mice before
testing it in tumour-bearing animals. A single bolus IP dose (0, 0.2,
1, 5 mg) of KLK10 or daily IP injections (0, 0.05, 0.2, 0.8 mg) for
14 consecutive days were both well tolerated with no changes in
body mass or general wellness, and no visible toxicity upon review
of tissue sections of the liver, lung, heart and kidney (data not
shown). The drug was judged safe and suitable for treatment of
tumour-bearing animals, with doses of up to 5 mg being
completely cleared of the blood by 12 h (Fig. 4A).
To test the efficacy of the recombinant KLK10, IP doses of
5 mg were administered once or twice daily for 14 days and
compared to PBS injected control in the ES-2 xenograft model.
Statistically significant increases in survival were observed in
animals treated with recombinant KLK10 at 5 mg once daily
(p,0.05), and twice daily (p,0.01), and one complete responder
Table 3. Nude mice xenografted with ES-2 derived clones overexpressing KLK5, 6 and 10 alone or in pairs, develop different
pathophysiologies.
Groups N
Ascites
incidence
(%)
Mean ascites
volume (ml)
Aggregates
(%)
Mean KLK
concentration in
ascites (ng/ml)
Mean tumour
burden (g)
Median KLK
detection onset
(days)
Median
symptom
onset (days)
Parental 7 100 3.9760.52 85.7 ND 0.7260.16 N/A 13
Single vector 8 87.5 2.5760.79 85.7 ND 1.3460.19 N/A 16.5
KLK5 8 75 3.7060.58 33.3 9056352 1.6560.17 12 21
KLK6 8 87.5 3.9760.51 71.4 522 1.1560.18 5 14
KLK10 8 87.5 3.8660.40 0* 36806850 1.5360.16 19.5 24.5
Double vector 8 100 8.2360.38 100 ND 1.4060.15 N/A 13
KLK5/6 8 75 4.2560.73 0* KLK5 18906836
KLK6 12906513
1.2660.16 8 20
KLK5/10 8 37.5* 3.5260.87 0* KLK5 3936112
KLK10 4646301
2.3460.23 14 21
KLK6/10 8 37.5* 4.0061.58 0* KLK6 16126684
KLK10 1661861230
3.9760.42 7 16.5
ND=not detectable; N/A=not applicable;
*denotes statistical significance relative to appropriate control at p,0.05 by CHI-square or one-way ANOVA where applicable. Mean values are indicated 6 SEM.
doi:10.1371/journal.pone.0026075.t003
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Tumour burden and ascites volume did not differ from control in
treated mice (Fig. S1), and disease presentation such as aggregates
in ascites or sites of metastasis was not qualitatively different (data
not shown).
The recombinant KLK10 doses injected IP lead to plasma
concentrations orders of magnitude higher at one hour (Fig. 4A)
than the highest doses recorded in KLK10 tumour-bearing mice
(Table 3), albeit transiently. To investigate if such doses could be
cytotoxic, ES-2 cells were treated in vitro with increasing
concentrations of recombinant KLK10 for 96 h in the presence
or absence of serum. Recombinant KLK10 caused significant cell
death when compared to PBS-treated control, although this effect
was completely inhibited by adding 10% serum to the culture
media (Fig. 4C).
Discussion
This study revealed for the first time a correlation between
expression of multiple kallikreins (KLK5, 6, 8, 10, 13 and 14) and
reduced aggressivity in a panel of 13 ovarian cancer cell lines. Of
the kallikreins tested, KLK5, 6 and 10, were the most consistently
expressed in cell lines with a less aggressive phenotype, which were
incapable of forming colonies in soft agar, invading matrigel or
forming tumours in nude mice. Paradoxically, KLK5, 6 and 10
are expressed in a high proportion of ascites of ovarian cancer
patients [52], and they have previously been associated with poor
patient prognosis in ovarian cancer [37]. KLK5, 6 and 10 are
detectable in the ascites of ovarian cancer patients at the relatively
high average concentrations of 62.2 ng/ml, 144 ng/mL, and
57 ng/ml respectively [16], however few studies have addressed
the differences in ascites and serum concentrations of kallikreins on
the basis of histological subtypes in a large cohort of ovarian
cancer patients. Furthermore, the role of kallikreins in ovarian
cancer progression has been scarcely studied outside of prognostic
and diagnostic applications, and reports of their effects in other
cancers have been contradictory, in large part due to their
pleiotropic and sometimes opposing effects on cell viability and
apoptosis, metastasis, angiogenesis, tissue remodeling and EMT
[37]. Because kallikreins often act in a cascade and at least 12
kallikreins are concomitantly upregulated in ovarian cancer it is
difficult to parse the individual contribution of each kallikrein to
the pathophysiology of this disease.
To systematically investigate the contributions of KLK5, 6 and
10 to ovarian cancer development, the ES-2 cell line was used,
since it did not express any of the kallikreins tested and readily
forms tumours in nude mice. The ES-2 ovarian cancer cell line
was originally derived from a patient with a clear cell tumour [53],
however when xenografted it is known to make undifferentiated
tumours [39]. From this cell line we generated clones overex-
pressing KLK5, 6 and 10 alone or in pairs. The resulting clones
displayed altered anchorage-independent growth in vitro, as well as
varying aggressivity in vivo as measured by survival of xenografted
nude mice. Cells overexpressing KLK5, 5/6, 5/10, and 6/10
produced significantly fewer colonies in soft agar than vector-
transfected controls. Similarly, mice xenografted with cells
overexpressing KLK10, 5/6, 5/10, 6/10 had a significant survival
advantage over their respective control mice, while mice with
KLK6-secreting tumours had significantly decreased survival. The
increased survival of the KLK10 group was reminiscent of the
Figure 3. Plasma kallikrein levels reflect the progression of the disease in xenografted mice. Plasma kallikrein levels were recorded
weekly by ELISA in the mice xenografted with ES-2 clones overexpressing of KLK5, 6 and 10, alone or in pairs. The last three weekly measurements
before endpoint of individual mice were plotted as the mean concentration of the group +/2 SEM.
doi:10.1371/journal.pone.0026075.g003
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line overexpressing KLK10 observed by Goyal et al [44]. This
observation further supports the hypothesis of KLK10 as a
putative tumour suppressor, silenced in prostate, testicular, and
breast cancer as well as in acute lymphoblastic leukemia.
Furthermore, it may be that the ES-2 cell line is exquisitely
sensitive to overexpression of KLK10 since, in these cells, the
KLK10 locus is hypermethylated, suggesting that silencing
contributed to its transformation [36]. In contrast to the KLK10
group, the mice xenografted with cells overexpressing KLK6 died
significantly earlier than the control mice. The increased
aggressiveness of the KLK6 clone was not unexpected as KLK6
overexpression is thought to be an early phenomenon in ovarian
carcinoma development [25]. KLK6 has been associated with
increased invasiveness, growth and angiogenesis, by virtue of its
ability to degrade ECM components such as denatured type I
collagen, fibronectin, vitronectin and laminin [54], or activate
PAR-2 signaling [55] which has been implicated in mediating
cellular proliferation in colon cancer cells [56].
The importance of the specific mix of kallikreins present and
their relative abundance on the activome is underscored by the
drastic difference within our clones, and with other published
reports such as the findings of Prezas et al. [57] who have shown
that the OV-MZ-6 ovarian cancer cell line engineered to co-
express KLK4/5/6/7 displayed an increased tumourigenicity.
Furthermore, the data suggests that some kallikreins may have
dominant or inactivating/activating effects over other kallikreins,
suggesting for example that the drastically different behaviour of
KLK6 versus KLK5/6 clones, could be due to the ability of
KLK5 to inactivate other kallikreins in vitro [58]. Conversely
animals with tumours expressing a combination of KLK6/10
behave differently than their single expressing counterparts
suggesting that the kallikreins can interact. The basis of this
interaction may rely on the ability of KLK6 to cleave and activate
itself [29], while KLK10’s function may be independent of
enzymatic activity since it appears to be catalytically inactive in vivo
[52]. Finally, the relative abundance of serum kallikreins as
measured in the xenografted mice prior to endpoint suggest that
dosage may play an important role in the phenotype: the high
concentration of KLK10 in both the single expresser and the
KLK6/10 group may explain the strong protective effect of
KLK10. Taken together these results suggest that kallikreins 5, 6
and 10 can mediate effects important for tumourigenicity, and
their interactions may be complex and dependent on the
kallikreins’ activome and the relative abundance of the various
kallikreins.
To understand the mechanisms underlying the survival
differences, it was possible to exploit the fact that the implanted
tumours secreted kallikreins into the blood and ascites, thus
providing us with a means to track tumour burden. The use of
Figure 4. Treatment of mice xenografted with ES-2 cells with various IP doses of recombinant KLK10. A) Mice were injected with a bolus
of recombinant KLK10 IP and blood samples were taken at different time intervals to measure plasma concentrations of KLK10 by ELISA. B) Mice were
injected IP with either PBS or recombinant KLK10 daily or twice daily for 14 days post xenograft with ES-2 in a survival experiment. C) ES-2 cells were
treated with various doses of recombinant KLK10 (0, 0.3, 3, 30 mg/ml) for 96 h in serum-free or serum-containing media and cell viability was
determined by trypan blue exclusion. * denotes p,0.05, ** denotes p,0.01, and *** p,0.001.
doi:10.1371/journal.pone.0026075.g004
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ed in the clinic, most notably with KLK3 (PSA) in prostate cancer
[59–61]. It has also been suggested that both KLK6 and KLK10
could be useful diagnostic biomarkers, which, combined with CA-
125 can increase the sensitivity of the screening test [22]. Similarly
we detected kallikreins 5, 6, and 10 in the circulation well before
the onset of any symptoms, and their levels increased as disease
progressed, only to peak at necropsy. Interestingly, the disease-free
surviving mice of groups KLK5, KLK5/6, KLK5/10 and KLK6/
10, never displayed any detectable levels of kallikreins, suggesting a
failure to implant or to grow to a detectable size. From these
combined data, it is possible to infer that some of the survival
effects of kallikreins 5, 6 and 10 are mediated by an inhibition of
tumour implantation, possibly because of inhibition of anchorage-
independent growth.
The finding that the disease phenotype also varied qualitatively
amongst groups gave insights into the contribution of kallikreins to
the pathophysiology of ovarian cancer. The most common
endpoint in the survival experiment was distension as a result of
ascites, therefore, a reduction in the incidence of ascites can have a
large influence on survival despite rarely causing mortality in
patients. As such, groups KLK5/10 and KLK6/10 had a marked
reduction in the incidence of ascites and a corresponding longer
survival. While the mechanisms by which KLK5, 6 and 10
influence ascites formation has not yet been established, kallikreins
are known to mediate processes such as inflammation, oedema,
angiogenesis and blood pressure [2], all of which are relevant to
ascites accumulation [56,62,63]. Furthermore all groups which
had a survival advantage had a marked reduction in the incidence
of aggregates in the ascites, possibly because the effect of kallikreins
on anchorage-independent growth. Aggregates in the ascites of
ovarian cancer patients have previously been identified, and may
contribute to the spreading of the disease [64]. Taken together,
these results raise the possibility that KLK5, 6 and 10 play an
inhibitory role in the formation of ascites and the cellular
aggregates within it, which consequently reduces the morbidity
and mortality of the mice. While tumour burden, ascites volume,
or sites of metastasis do not generally differ at endpoint, this is an
artifact of the endpoints used in this study since animals reaching a
common set of criteria before being sacrificed does not reflect
differences in the rate of progression of these attributes.
Paradoxically, all three kallikreins tested are already known to
be elevated in ascites of patients [46,52], particularly KLK6, albeit
at lower levels than what was recorded in the ascites of mice in this
study. It is tempting to speculate that patients with high levels of
circulating KLK10, particularly in combination with low or null
amounts of KLK6, may be less prone to ascites accumulation and
those ascites may be less likely to contain cellular aggregates.
The positive and dominant effects of KLK10 on overall survival
make it an attractive putative therapeutic agent for ovarian cancer.
To test this prospect, a recombinant protein was generated, which
was found to be devoid of proteolytic activity, in accordance with
earlier published studies [22]. The recombinant KLK10 protein
was injected into the peritoneum to maximize the exposure of
peritoneal tumours and detached cellular aggregates to the drug.
The recombinant KLK10 was well tolerated at up to 5 mg,
although only a fraction of the drug was detected in the
circulation, and it was quickly cleared from the blood. Remark-
ably, the recombinant KLK10, despite being present only
intermittently, was sufficient to significantly increase survival of
treated mice at doses of 5 mg once or twice daily, and the study
concluded with one mouse without detectable disease. While we
do not know whether the cells failed to implant in the presence of
KLK10 at the time of injection, or the tumours regressed later
during the treatment, the substrate-dependent growth of the clones
suggest the former.
The molecular pathway by which the catalytically inactive
KLK10 exerts its biological effects remains elusive, despite the
accumulating evidence of its tumour-suppressing qualities. In vitro
results suggest KLK10 may be cytotoxic to cancer cells at high
concentrations and that a component of fetal calf serum can
inhibit this toxicity. It is unclear how KLK10 may mediate its anti-
tumour effects, however the absence of toxicity in mice and the
potent in-vitro response to the recombinant KLK10 peptide
suggest a promising therapeutic window. Taken together these
results indicate that the effects observed with the KLK10 secreting
clones on survival and on the pathophysiology are specific to
KLK10 and could be partially recapitulated with a recombinant
protein, suggesting it may have therapeutic value. Finally these
findings support the hypothesis that KLK10 is a tumour
suppressor and further underline the involvement of KLK5, 6
and 10 in ovarian pathophysiology.
Supporting Information
Figure S1 Ascites volume and tumour burden of
xenografted mice treated with recombinant KLK10. A)
The ascites volume was measured at endpoint in mice treated with
either PBS or one or two doses of recombinant KLK10 per day. B)
tumour burden, as defined as total mass or excisable tumour at
endpoint was recorded in the same treatment groups.
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